RHEINFELDEN, Switzerland, 06.04.2023 - Tillotts Pharma AG (“Tillotts”), part of the Japanese Zeria Group, is pleased to announce the recent launch of Octasa® 1600 mg (mesalazine) delayed-release tablets as first-line treatment for moderately active ulcerative colitis (UC) in Canada.
The expansion of the Octasa® family in Canada with the launch of Octasa® 1600 mg represents an important step in the strategic partnership of Tillotts Pharma AG with Pendopharm and a milestone for both organizations.
The introduction of Octasa® 1600 mg (mesalazine) delayed-release tablets to the Canadian market is expected to increase the options for UC patients managed with mesalazine.
Adrian Hill, Global Head of Commercial Operations at Tillotts, said:
“Tillotts has a longstanding history of more than 40 years in delivering mesalazine formulations for the treatments of patients suffering from UC, and I am very excited about the opportunity to strengthen our commercial presence in Canada by launching Octasa® 1600 mg tablet as a new high strength mesalazine tablet treatment option.
This has been achieved through the solid strategic partnership between Tillotts and Pendopharm.”
Jad Isber, Vice President and General Manager at Pendopharm, added:
"Earlier this year, we announced the launch of Octasa® 800 mg, and we are delighted to continue our strong relationship with Tillotts by bringing Octasa® 1600 mg to Canadian patients suffering from moderately active ulcerative colitis. The addition of Octasa® 1600 mg to our portfolio will further enhance Pendopharm’s leadership position in gastroenterology, bringing a new treatment option to healthcare professionals and patients."
For more information, please contact:
Tillotts Pharma AG
Jeroen van Anraat
Manager Corporate Communications
Phone: +41 79 692 63 91
Tillotts Pharma AG, part of the Japanese Zeria Group, is a fast-growing specialty pharma company with over 350 employees in Switzerland and abroad. Tillotts is dedicated to the development, acquisition and commercialisation of innovative pharmaceutical products for the digestive system. Tillotts successfully markets its own products for the treatment of IBD and Clostridioides difficile infection (CDI) as well as in-licensed products in around 65 countries through its affiliates within Europe and a network of partners throughout the world.
The rights to the trademark Octasa® are owned by Tillotts. Copyright© by Tillotts Pharma AG 2022. All rights reserved.
For more information, please visit www.tillotts.com
Zeria Pharmaceutical Co., Ltd., founded in 1955, based in Tokyo, Japan, focuses on R&D, manufacturing and sales of prescription drugs as well as OTC products. The company is listed on the First Section of Tokyo Stock Exchange (Stock code: 4559). Zeria holds a leading position within the gastroenterology field in Japan and operates internationally through a number of subsidiaries. For more information about Zeria, please visit www.zeria.co.jp
About Pharmascience Inc.
Pharmascience Inc. is one of the largest pharmaceutical manufacturers in Canada and is headquartered in Montreal, Canada. Pharmascience delivers high-quality medicines to over 50 countries worldwide. Pharmascience’s global presence and agile business development model provide healthcare communities around the world with the high-quality Canadian medicines to respond to patients’ needs.
Pendopharm, division of Pharmascience Inc., is a leading Canadian specialty pharmaceutical company providing patients with innovative medicines that address unmet medical needs. Its areas of focus are gastroenterology, sports medicine & orthopedics, neurology and cardiology. Pendopharm has extensive experience and knowledge to successfully manage its growing product portfolio.
For more information about Pendopharm, please visit www.pendopharm.com.
For media inquiries, please contact MediaInquiries@pharmascience.com.
© 2023 Pendopharm, division of Pharmascience Inc. All rights reserved